Bill & Melinda Gates foundation - Ken Duncan

1,670 views

Published on

Partnerships in drug discovery and development for diseases of the developing world

  • Be the first to comment

Bill & Melinda Gates foundation - Ken Duncan

  1. 1. Partnerships in drug discovery and development for diseases of the developing world Ken Duncan BioDundee, Dundee 29 May, 2013
  2. 2. 2 TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  3. 3. 3 TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  4. 4. © 2010 Bill & Melinda Gates Foundation | Our Belief ALL LIVES —NO MATTER WHERE THEY ARE BEING LIVED— HAVE EQUAL VALUE
  5. 5. Our History Bill and Melinda read an article about rotavirus They officially create the foundation Warren Buffett decides to give Berkshire Hathaway stock 1998 2000 2006 2008 Bill joins Melinda full-time at the foundation
  6. 6. $36.4 billion Asset trust endowment $26 billion Grants Since inception 1,100 Employees worldwide $3.4 billion 2012 grants payments $31.3 billion Warren Buffet pledge Headquarters: Seattle Offices: London, Washington DC Country Offices: China, India Country Representatives: Ethiopia, South Africa, Nigeria Reach & Presence
  7. 7. What We Focus On What are the areas of greatest need? Where can we have the greatest impact?
  8. 8. United States Program Global Health Program Global Development Program Programs
  9. 9. 2011 Grants Paid Summary For the year ended December 31, 2011. Amount in thousands. (by Program Area) Global Health $1,977,507 Global Development $667,780 United States Program $486,917 Operations/Non-Program Grants $48,466 Strategic Media Partnerships $18,379 Policy & Government Affairs $9,117
  10. 10. Integrated Approach for Global Health VACCINES VECTOR CONTROL SANITATION FAMILY HEALTH DRUGS DIAGNOSTICS
  11. 11. How Our Strategies Align All strategies seek transformational change. All strategies rely on partners and grantees to carry out the work. All strategies emphasize technology.
  12. 12. TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  13. 13. Drug discovery priorities Malaria Helminths Diarrheal Disease TB Platforms
  14. 14. Drug discovery priorities Malaria Bell et al. Nature Reviews Microbiology 4, S7–S20 (2006)SERCaP (Single Encounter Radical Cure and Prophylaxis) Target Product Profile
  15. 15. Drug discovery priorities Helminths Onchocerciasis: "River Blindness" Lymphatic Filariasis: "Elephantiasis" Macrofilaricide Kill Adult worms Safe in Loa loa regions Target Product Profile
  16. 16. Drug discovery priorities TB Novel combination Shorter, safer treatment Overcome MDR-TB Target Product Profile
  17. 17. Drug discovery priorities Diarrheal Disease Adapted from The Global Burden of Disease: 2004 Update; WHO Anti-secretory Boost ORS effectiveness Increase ORS compliance Target Product Profile
  18. 18. Drug discovery priorities Platforms
  19. 19. Grantees and partners Target Lead Candidate Lead Optimisation Target validation Pre-clinical Clinical Development Lead Identification Target identification Product Development Partnerships Academia, Institutes Pharma Biotech
  20. 20. TOPICS 1. Introduction to the work of the Bill & Melinda Gates Foundation 2. Drug discovery portfolio 3. Importance of partnerships in TB drug discovery and development
  21. 21. TB treatment today 6-24 months Multiple drugs Isoniazid Rifampicin Pyrazinamide Ethambutol Complexity: DOTS Safety, drug-drug interactions The World needs a shorter, safer drug regimen
  22. 22. Bedaquiline, first new TB drug approved in over 40 years December 31, 2012
  23. 23. Importance of Partnerships Target Lead Candidate Lead Optimisation Target validation Pre-clinical Clinical Development Lead Identification Target identification TBDA CPTR
  24. 24. 24
  25. 25. CPTR: A new development paradigm
  26. 26. TBDA Next generation therapy Goal: A new first line drug regimen that works in one month or less Problem: Few new drug candidates, little diversity Solution: An integrated cross-industry- academia discovery partnership Challenge:
  27. 27. TBDA The TBDA is a groundbreaking partnership between seven pharmaceutical companies and six research institutions collaborating on early TB drug discovery The TB Drug Accelerator How it works… Company Compound Libraries Collaborative Discovery Research 5 new preclinical candidates 2016 1 month regimen proof of concept 2021 • Hit and Lead Generation • Target Identification • Lead Optimization Research Institutions: Pharmaceutical Companies: With support from:
  28. 28. TBDA The TBDA is a New Paradigm For Drug Discovery The TBDA offers a new approach that addresses many of the bottlenecks in the way TB drugs are currently developed ONLY THE BEST CANDIDATES ADVANCE Early Collaboration Avoid Redundancy Data Sharing Maximize Efficiency Overcome Competitive Barriers Companies Work on Each Other’s Compounds
  29. 29. TBDA • Partnerships such as the TBDA show how industry and others can work together in new ways to support global health innovation • The TBDA model could be applied to other disease areas that lack incentives for research or require combination drug therapies The TBDA Offers a Model for Other Initiatives
  30. 30. EVERY PERSON DESERVES THE CHANCE TO LIVE A HEALTHY, PRODUCTIVE LIFE.
  31. 31. All Rights Reserved. Bill & Melinda Gates Foundation is a registered trademark in the United States and other countries. Learn More www.GatesFoundation.org www.ImpatientOptimists.org BillandMelindaGatesFoundation @GatesFoundation

×